Recent Updates
Recently added Catalysts
ANRO Negative Sentiment Score: 25/100

ALTO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against Alto Neuroscience, Inc. (ANRO) by Bragar Eagel & Squire, P.C. This legal action is on behalf of investors who acquired Alto securities between February 2, 2024, and October 22, 2024. The lawsuit claims that Alto failed to adequately disclose the ineffectiveness of ALTO-100 in treating major depressive disorder (MDD), leading to an overstated impression of the company's financial and commercial prospects. Following disappointing clinical trial results, Alto's stock experienced a significant decline.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Alto Neuroscience, suggesting potential legal troubles.
  • The IPO documents were allegedly negligently prepared, indicating possible misleading information to investors.
  • ALTO-100 failed to meet its primary endpoint in a clinical trial for treating MDD, which negatively affected the company's credibility.
  • Following the announcement, Alto's stock price plummeted nearly 70%, indicating investor loss.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE:ANRO) in the United States District Court Northern District Of California on behalf of all persons and entities who purchased or otherwise acquired Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). Investors have until September 19, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
According to the complaint, the Offering Documents in support of the IPO were negligently prepared. Additionally, during the class period, defendants failed to disclose that: (i) ALTO-100 was less effective in treating MDD than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Alto’s business and/or financial prospects were overstated.
On October 22, 2024, Alto issued a press release announcing topline results from the Phase 2b trial evaluating ALTO-100 as a treatment for MDD. That press release stated, in relevant part, that “ALTO-100 in patients with [MDD] did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.” On this news, Alto’s stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
If you purchased or otherwise acquired Alto shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should contact Brandon Walker about Alto (ANRO)?

Investors who suffered losses in Alto between February 2, 2024, and October 22, 2024.

What legal action is being taken against Alto Neuroscience?

A class action lawsuit has been filed regarding their IPO documents' negligence.

What caused Alto’s stock price to drop significantly?

The failure of ALTO-100 to meet primary endpoints in its Phase 2b trial.

How can investors learn more about their claims?

They can contact Brandon Walker or Marion Passmore via phone or email.

Is there a cost for investors to discuss their options?

No, there is no cost or obligation for investors to inquire.

Last updated: Sep 7, 2025